Cinacalcet for the treatment of hypercalcemia with persistent hyperparathyroidism in renal transplant recipients: a case siries study.
Not Applicable
Completed
- Conditions
- Hypercalcemia with persistent hyperparathyroidism in renal transplant recipients.
- Registration Number
- JPRN-UMIN000003236
- Lead Sponsor
- St Marianna University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1.age below 20 years old or pregnant 2.those who cannot agree to the study 3.inappropriate patients judged by primary or study physicians. 4.history of allergy or severe side effects by cinacalcet 5.those with severe liver dysfunction 6.concomitant use of vitamin D sterols, phosphate binder, calcium supplementation, bisphosphonates within 2 weeks before start of the study 7.history of parathyroidectomy or percutaneous ethanol injection therapy to parathyroid glands.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cinacalcet's effect on calcium homeostasis in renal transplant recipients with persistent hyperparathyroidism?
How does cinacalcet compare to calcimimetic agents in managing hypercalcemia post-renal transplant?
Are there specific biomarkers that predict response to cinacalcet in patients with persistent hyperparathyroidism following renal transplantation?
What are the potential adverse events associated with cinacalcet use in renal transplant recipients and how can they be managed?
What combination therapies involving cinacalcet show promise for treating hyperparathyroidism-related hypercalcemia in renal transplant patients?